Obesity is one of the biggest health problems facing the world today. The number of people living with obesity has increased rapidly over the past few decades, affecting both adults and children.
Obesity is much more than carrying extra body weight. It is a complex medical condition that raises the risk of many serious diseases, including heart disease, stroke, type 2 diabetes, fatty liver disease, high blood pressure, sleep apnea, and several types of cancer. Losing weight is often very difficult, and many people regain the weight they lose.
Although healthy eating and regular exercise remain the foundation of weight management, these approaches do not always work well on their own. Safe and effective medicines are still limited, especially for people with severe obesity.
Researchers at Johns Hopkins Medicine have discovered a promising new approach that may one day help millions of people. Their research focuses on a medicine that was originally developed to treat Alzheimer’s disease, schizophrenia, and sickle cell disease.
Although the drug was not successful for those conditions, scientists have found that it may have a completely different use—helping prevent obesity and improving several health problems linked to excess body fat.
The medicine works by blocking an enzyme called phosphodiesterase 9, or PDE9. Enzymes are proteins that help control many chemical reactions inside the body.
PDE9 affects a signaling molecule called cyclic GMP, which plays an important role in regulating metabolism, blood vessels, heart function, and the way cells communicate. When PDE9 is blocked, the body appears to burn energy more efficiently instead of storing it as fat.
The researchers first became interested in PDE9 after earlier studies in 2015 showed that the enzyme could worsen heart disease, especially in people with high blood pressure. This led them to wonder whether blocking PDE9 might also improve other health conditions related to obesity.
To investigate, the scientists tested a PDE9 inhibitor called PF-04447943 in mice. This drug was originally developed by Pfizer for Alzheimer’s disease. Although it did not improve Alzheimer’s symptoms, it had already been tested in more than 100 people and appeared to be safe, with no serious side effects reported during those early clinical trials.
The results in mice were encouraging. Animals treated with the drug gained much less weight than untreated mice, even though they did not eat less food or exercise more.
The treatment also reduced fatty liver disease, improved heart health, lowered blood sugar levels, reduced harmful blood fats such as cholesterol and triglycerides, and decreased excess fat stored around the abdomen. These findings suggest that blocking PDE9 changes the way the body handles energy rather than simply reducing appetite.
One of the most interesting findings is that the treatment challenges the common belief that obesity is caused only by eating too much or exercising too little. The study suggests that biology also plays an important role.
Enzymes, hormones, genes, and metabolism can all influence how easily people gain or lose weight. Understanding these biological factors may lead to better treatments that work alongside healthy lifestyle changes.
Researchers estimate that if the same effects seen in mice are eventually confirmed in humans, a person weighing about 250 pounds could potentially lose around 50 pounds while taking a PDE9 inhibitor.
However, this prediction is based on animal studies and has not yet been proven in people. Much more research is needed before doctors can know whether the medicine is truly effective and safe for long-term treatment of obesity.
The study was led by Dr. David Kass and published in the Journal of Clinical Investigation. The researchers stress that people should not expect this treatment to become available immediately. Human clinical trials are still needed to confirm the results and determine the best dose, long-term safety, and possible side effects.
Even so, the discovery offers real hope. If future studies produce similar results in people, PDE9 inhibitors could become a completely new way to treat obesity and many of its related health problems.
Instead of focusing only on diet and exercise, future treatments may also target the body’s biology, giving millions of people another tool to achieve healthier lives.
If you care about Alzheimer’s disease, please read studies about vitamin D deficiency linked to Alzheimer’s and dementia, and strawberries can be good defence against Alzheimer’s.
For more health information, please see recent studies about foods that reduce Alzheimer’s risk, and oral cannabis extract may help reduce Alzheimer’s symptoms.
Copyright © 2026 Knowridge Science Report. All rights reserved.
